Summit Trail Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

Summit Trail Advisors’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3,650	Closed	-$225K	–	251
2018 Q3	$225K	Buy	3,650 +925	+34%	+$59.5K	0.05%	180
2018 Q2	$184K	Sell	2,725 -9,197	-77%	-$515K	0.06%	148
2018 Q1	$440K	Buy	11,922 +1,283	+12%	+$71.8K	0.07%	224
2017 Q4	$596K	Buy	+10,639	New	+$645K	0.08%	205

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Summit Trail Advisors's AERI Position: Q4 2018 in Review

Summit Trail Advisors sold out of Aerie Pharmaceuticals (AERI) in Q4 2018, closing a stake of 3,650 shares — an estimated $225K sold.

Summit Trail Advisors first reported a position in AERI in Q4 2017 and held it in 4 quarters. The position peaked at $596K in Q4 2017. 160 funds tracked by Wall St. Rank hold AERI as of Q4 2018.

Summit Trail Advisors reported no remaining Aerie Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Summit Trail Advisors sold 3,650 Aerie Pharmaceuticals shares in Q4 2018, an estimated $225K.
Summit Trail Advisors first reported a position in Aerie Pharmaceuticals in Q4 2017 and held it in 4 quarters.
Summit Trail Advisors's Aerie Pharmaceuticals position peaked at $596K in Q4 2017.
160 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2018.

Based on Summit Trail Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.